Zurich Cantonal Bank
SPRY icon

Zurich Cantonal Bank’s ARS Pharmaceuticals SPRY Stock Holding History

Zurich Cantonal Bank’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$166K Buy
38,579
+13,930
+57% +$81.4K ﹤0.01% 2374
2026
Q2 		$197K Buy
24,649
+12,987
+111% +$112K ﹤0.01% 2308
2026
Q1 		$93.6K Buy
+11,662
New +$112K ﹤0.01% 2387
2025
Q4 		– Sell
-11,662
Closed -$113K – 3387
2025
Q3 		$117K Buy
11,662
+4,243
+57% +$60.9K ﹤0.01% 2353
2025
Q2 		$129K Hold
7,419
– – ﹤0.01% 2311
2025
Q1 		$93.3K Hold
7,419
– – ﹤0.01% 2408
2024
Q4 		$78.3K Hold
7,419
– – ﹤0.01% 2502
2024
Q3 		$108K Hold
7,419
– – ﹤0.01% 2399
2024
Q2 		$63.1K Buy
7,419
+4,472
+152% +$39.7K ﹤0.01% 2504
2024
Q1 		$30.1K Sell
2,947
-1,746
-37% -$13K ﹤0.01% 2606
2023
Q4 		$25.7K Sell
4,693
-1,068
-19% -$4.68K ﹤0.01% 2647
2023
Q3 		$21.8K Sell
5,761
-575
-9% -$3.77K ﹤0.01% 2701
2023
Q2 		$42.5K Buy
6,336
+3,486
+122% +$23.3K ﹤0.01% 2650
2023
Q1 		$18.6K Buy
+2,850
New +$21.9K ﹤0.01% 2766

Other funds holding SPRY

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Tyro Capital Management
Tyro Capital Management Miami, Florida $564M AUM 72.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $52.3B AUM 19.7% 1-Year Est. Return
Creek Drive Management Group
Creek Drive Management Group San Francisco, California $368M AUM 23.05% 1-Year Est. Return

Zurich Cantonal Bank's SPRY Position: Q3 2026 in Review

Zurich Cantonal Bank increased its ARS Pharmaceuticals (SPRY) stake by 57% in Q3 2026, buying an estimated $81.4K and bringing the position to 38,579 shares worth $166K. The position accounts for ﹤0.01% of the portfolio, ranked #2374.

Zurich Cantonal Bank first reported a position in SPRY in Q1 2023 and has held it in 14 quarters since. The position peaked at $197K in Q2 2026. 133 funds tracked by Wall St. Rank hold SPRY as of Q3 2026.

  • Zurich Cantonal Bank held 38,579 shares of ARS Pharmaceuticals worth $166K as of Q3 2026.
  • Zurich Cantonal Bank bought 13,930 ARS Pharmaceuticals shares in Q3 2026, an estimated $81.4K.
  • ARS Pharmaceuticals made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q3 2026, its #2374 holding.
  • Zurich Cantonal Bank first reported a position in ARS Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
  • Zurich Cantonal Bank's ARS Pharmaceuticals position peaked at $197K in Q2 2026.
  • 133 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2026.

Based on Zurich Cantonal Bank's 13F filing for Q3 2026, filed 10 Nov 2026.